Rocket Pharmaceuticals, US FDA Agree on Design of Mid-Stage

-- Rocket Pharmaceuticals said Wednesday it has reached an agreement with the US Food and Drug Administration on the design of its phase 2 trial of RP-A501 in Danon Disease, a genetic disorder...

Related Keywords

, Rocket Pharmaceuticals Inc , Rocket Pharmaceuticals , Fanconi Anemia , Leukocyte Adhesion Deficiency I , Pyruvate Kinase Deficiency , Danon Disease , Markets ,